Parabolic Drugs Ltd., a vertically integrated API manufacturer and exporter in India, announced the unaudited results for quarter and full year ended 31st March, 2012.
Sales increased by 50.3% to Rs. 1014.9 crore during FY12 as compared to Rs. 675.3 crore in FY11
Net profit at Rs. 51.4 crore as compared to Rs. 52.9 crore in FY11
EBITDA increased by 28.5% to Rs. 163.3 crore in FY12
The companys EBITDA margin maintained at 17.8%
Key highlights during FY 12 include:
Commissioning of multi-purpose block 3 with 120 TPA capacity and spray dryer for augmenting Amorphous Cephalosporin
Commissioning of New Sterile facility in March 2012 with fully automated International BA-DO machinery for World class quality and compliance.
Successful audit checks from Japanese, Korean and European regulators
Successful commissioning of Lalru facility to manufacture lifestyle drugs and non-antibiotics with a pipeline of 17 new drugs
Foray into the domestic formulations space with NUCLEUS brand consisting of almost 150 products.
Successful ution of 35 projects in the CRAMS space
Making inroads into the herbal nutraceutical space
Vineet Gupta, Director, Parabolic Drugs, said, The fiscal year gone past has been a momentous one for the Company not only in terms of revenue and profitability but also with respect to various developments on the business front. Key developments included the commis-sioning of the Lalru facility for lifestyle drugs, expansion of plant at Derabassi to manufacture Amorphous Cephalosporin, foray into the Domestic Formulations space and significant business devel-opment efforts in the CRAMS space. FY 12 also marked our presence in Japan and new regulatory markets. We are confident that the investments that we have made this year will translate into signifi-cant growth opportunities for the Company in the future.